Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Werewolf Therapeutics ( (HOWL) ).
Werewolf Therapeutics announced the passing of Dr. Alon Lazarus, a Board member, on September 30, 2025. His death left the company’s Audit Committee noncompliant with Nasdaq’s listing rules, prompting the company to plan for appointing a new independent director to regain compliance.
The most recent analyst rating on (HOWL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.
Spark’s Take on HOWL Stock
According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.
The overall stock score of 48 reflects significant financial challenges, with ongoing losses and negative cash flows being the most impactful factors. While technical analysis shows some short-term bullish momentum, the negative valuation metrics due to losses weigh heavily on the score. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on HOWL stock, click here.
More about Werewolf Therapeutics
Werewolf Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies.
Average Trading Volume: 458,231
Technical Sentiment Signal: Hold
Current Market Cap: $93.74M
See more insights into HOWL stock on TipRanks’ Stock Analysis page.